(R)-(-)-1-Benzyl-3-aminopyrrolidine (CAS No. 114715-39-8) Market (2026): Leading Players Driving Precision Drug Synthesis

MARKET INSIGHTS

Global (R)-(-)-1-Benzyl-3-aminopyrrolidine (CAS No. 114715-39-8) market size was valued at USD 18.6 million in 2025. The market is projected to grow from USD 19.8 million in 2026 to USD 34.2 million by 2034, exhibiting a CAGR of 7.1 % during the forecast period.

(R)-(-)-1-Benzyl-3-aminopyrrolidine is a chiral building block and pharmaceutical intermediate widely utilized in the synthesis of biologically active compounds. Characterized by its pyrrolidine ring structure with a benzyl group and an amine functionality, this enantiomerically pure compound plays a critical role in asymmetric synthesis, enabling the development of stereospecific drug candidates across therapeutic areas including central nervous system (CNS) disorders, anti‑infectives, and oncology.

The market is experiencing steady growth driven by rising demand for chiral intermediates in pharmaceutical manufacturing, increasing investment in drug discovery pipelines, and the expanding need for enantioselective synthesis in active pharmaceutical ingredient (API) production. Key suppliers and fine chemical manufacturers such as MilliporeSigma, Tokyo Chemical Industry, and Combi‑Blocks are among the prominent players supplying this compound to research institutions and pharmaceutical companies globally.

(R)-(-)-1-Benzyl-3-aminopyrrolidine (CAS No. 114715-39-8) Market – View in Detailed Research Report

Top 10 Companies in the (R)-(-)-1-Benzyl-3-aminopyrrolidine Market

1️⃣ MilliporeSigma

Headquarters: Burlington, Massachusetts, USA
Key Offering: Pharmaceutical‑grade (R)-(-)-1‑Benzyl‑3‑aminopyrrolidine, custom synthesis, analytical services

MilliporeSigma leverages its global R&D footprint to deliver high‑purity intermediates to early‑stage discovery and late‑stage manufacturing. The company’s integrated supply chain and cGMP‑compliant facilities enable rapid scale‑up for large‑volume API production.

Sustainability & Growth Initiatives:

• Investment in continuous‑flow synthesis to reduce waste and energy consumption
• Partnerships with major pharma to co‑develop chiral resolution processes
• Commitment to achieving net‑zero emissions by 2035 in chemical operations

2️⃣ Tokyo Chemical Industry (TCI)

Headquarters: Tokyo, Japan
Key Offering: Advanced chiral intermediates, enzymatic resolution kits, process chemistry support

TCI’s expertise in asymmetric catalysis positions it as a preferred supplier for CNS‑focused drug programs. The firm’s focus on modular process design facilitates rapid adaptation to new API requirements.

Sustainability & Growth Initiatives:

• Implementation of green solvent systems across production lines
• Strategic collaborations with academic institutions for novel biocatalytic routes
• Expansion of CDMO services in the Asia‑Pacific region

3️⃣ Pharmablock Sciences

Headquarters: Shenzhen, China
Key Offering: High‑purity chiral intermediates, rapid‑prototyping synthesis, contract manufacturing

Pharmablock Sciences serves as a flexible partner for mid‑size biopharma firms, offering scalable production with a focus on cost‑efficiency and speed to market.

Sustainability & Growth Initiatives:

• Adoption of biocatalytic processes to cut carbon footprint by 30 %
• Investment in local chemical parks to secure raw‑material supply
• Launch of a digital platform for real‑time batch monitoring

4️⃣ Combi‑Blocks Inc.

Headquarters: Cambridge, Massachusetts, USA
Key Offering: Modular chiral building blocks, custom synthesis, analytical validation

Combi‑Blocks’ modular approach allows rapid generation of diverse chiral scaffolds, supporting medicinal chemistry teams in lead optimization.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop water recycling in synthesis units
• Partnerships with universities for next‑generation catalyst development
• Expansion of product portfolio to include agrochemical intermediates

5️⃣ Enamine LLC

Headquarters: Kramatorsk, Ukraine
Key Offering: High‑purity chiral intermediates, combinatorial libraries, process optimization

Enamine’s strong focus on combinatorial chemistry provides a broad selection of chiral scaffolds, enabling rapid hit‑to‑lead progression.

Sustainability & Growth Initiatives:

• Transition to renewable energy sources for all production facilities
• Development of low‑toxic solvent alternatives
• Collaboration with biotech firms on platform‑based synthesis

6️⃣ SynQuest Laboratories, Inc.

Headquarters: North Carolina, USA
Key Offering: Custom synthesis, analytical services, chiral resolution

SynQuest’s expertise in stereoselective synthesis supports complex API development for oncology and CNS indications.

Sustainability & Growth Initiatives:

• Implementation of green chemistry metrics across projects
• Investment in automated synthesis platforms
• Expansion of services to include GMP‑ready production

7️⃣ AstaTech, Inc.

Headquarters: New York, USA
Key Offering: High‑purity chiral intermediates, rapid‑delivery services, analytical support

AstaTech’s focus on speed and reliability makes it a go‑to partner for late‑stage development programs.

Sustainability & Growth Initiatives:

• Adoption of energy‑efficient continuous processes
• Partnerships with logistics providers for carbon‑neutral shipping
• Launch of a sustainability reporting framework for clients

8️⃣ Matrix Scientific

Headquarters: New Jersey, USA
Key Offering: Pharmaceutical‑grade intermediates, custom synthesis, analytical validation

Matrix Scientific’s strong analytical capabilities support rigorous chiral purity verification, essential for regulatory submissions.

Sustainability & Growth Initiatives:

• Implementation of solvent‑recycling systems
• Development of biodegradable protective groups
• Expansion of service offerings to include process scale‑up

9️⃣ Apollo Scientific

Headquarters: London, United Kingdom
Key Offering: High‑purity chiral intermediates, rapid‑prototyping, analytical services

Apollo Scientific’s UK base allows quick access to European pharma pipelines, particularly in the CNS and oncology sectors.

Sustainability & Growth Initiatives:

• Adoption of ISO 14001‑certified production practices
• Partnerships with European research consortia on green synthesis
• Expansion of supply chain transparency tools for clients

🔟 Oakwood Chemical

Headquarters: Texas, USA
Key Offering: Pharmaceutical‑grade intermediates, custom synthesis, analytical support

Oakwood Chemical’s focus on quality and compliance makes it a trusted partner for high‑value API projects.

Sustainability & Growth Initiatives:

• Implementation of zero‑waste manufacturing protocols
• Investment in renewable energy for production sites
• Collaboration with regulatory bodies to streamline chiral purity validation

Download FREE Sample Report

Get Full Report

Outlook: The Future of (R)-(-)-1-Benzyl-3-aminopyrrolidine Market

The market is positioned to remain a strategic enabler for precision medicine, with continued expansion in CNS and oncology drug development. The convergence of biocatalysis, continuous flow chemistry, and digital process monitoring is expected to further lower costs and improve yield, reinforcing the compound’s role in next‑generation therapeutics.

Key Trends Shaping the Market

• Rapid adoption of enzymatic resolution techniques achieving >99 % ee at reduced cost
• Increased partnership between fine‑chemical manufacturers and CDMOs to accelerate API scale‑up
• Growing regulatory emphasis on chiral purity verification and real‑time release testing
• Expansion of Asia‑Pacific manufacturing capacity, driven by cost advantages and supportive government policies
• Integration of sustainability metrics into procurement decisions by major pharma players